Navigation Links
Phase 3 Cystic Fibrosis Trial Results Presented at European Conference
Date:6/15/2009

SYDNEY, June 16 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) is pleased to announce that additional results of its recently completed international Phase III trial of Bronchitol in patients with cystic fibrosis have been presented at the 2009 European Cystic Fibrosis Conference in Brest, France.

The results were presented to the conference on Friday 12 June by Dr Diana Bilton of the Royal Brompton Hospital, London.

The trial was a multi-centre, randomised, double blind, placebo controlled, 26 week study, with an optional further 6 month open label uncontrolled period. It was conducted in 40 centres in the United Kingdom, Ireland, Australia and New Zealand.

The primary endpoint of the trial was to assess whether Bronchitol improves lung function as measured by a change in FEV1 when administered twice per day for six months.

The key secondary endpoint of the trial was to assess whether Bronchitol further improves lung function in patients already being treated with the most commonly used CF therapeutic, rhDNase. Additional endpoints included changes in the Forced Vital Capacity of the lung, pulmonary exacerbations and antibiotic use.

Safety evaluation included the incidence of adverse events and the microbiology of sputum samples.

    Clinical Results
    -- There was a clinically meaningful change from baseline (119mL) and
       placebo (93mL) at week 26 with Bronchitol for FEV1 (p<0.001).
       Importantly, treatment with Bronchitol showed an immediate and
       sustained improvement in lung function (FEV1) over the 26 weeks
       (p<0.001).
    -- For the subgroup of patients on concomitant rhDNase there was also a
       significant improvement in FEV1 from baseline (88mL) and from placebo
       (109mL) at we
'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Three Lawrence Livermore researchers ... Hydrogen Production R&D Award for their research ... using sunlight. , Shared with collaborators from the ... of Nevada, Las Vegas (UNLV), the award recognizes ... photoelectrochemical solar-hydrogen production and corrosion processes. , These ...
(Date:8/29/2014)... A major challenge before new biotechnology start-up ... of Boston-Cambridge, is gaining visibility that can lead to ... Director of Boston’s Adult Stem Cell Technology Center, LLC ... of his company an important priority since he started ... a social media marketing campaign launched earlier ...
(Date:8/28/2014)... 28, 2014 SPIE Fellow Glenn Boreman, ... Optical Science and Director of the Center for Optoelectronics ... at Charlotte, and co-founder and Chairman of the Board ... the 2015 Vice President of SPIE, the international society ... Stahl announced recent election results at the Annual General ...
(Date:8/28/2014)... Best Sanitizers, Inc., the first company to ... asks food processors and food handling professionals to prepare ... currently using to Best Sanitizers’ Alpet® E3 Plus ... fighting cross-contamination and the spread of pathogens in the ... key criteria that make a hand sanitizer most effective, ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... to detect and respond to magnetic fields is not ... some bacteria and various migratory animals, do respond to ... turtles, this behavior involves small magnetic particles in the ... they are actually doing is not fully understood. ...
... and LONDON, Feb. 28, 2012  Thomson Reuters announced ... a new capability that speeds access to critical life ... premiere life sciences platform, Thomson Reuters Cortellis. ... uses sophisticated application programming interfaces (APIs) to ...
... Genetics Policy Institute  (GPI) joined the Coalition for ... ("friend of the court") brief in the United States Court ... funding for human embryonic stem cell research. ... Court and in the Court of Appeals, the latter in ...
Cached Biology Technology:The laws of attraction: Making magnetic yeast 2The laws of attraction: Making magnetic yeast 3Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services 2Genetics Policy Institute (GPI) Files Additional Legal Arguments in Sherley v. Sebelius Stem Cell Case 2
(Date:8/31/2014)... Warwick have discovered that ,good, cholesterol is turned ,bad, ... - MG, was found to damage ,good, HDL cholesterol, ... body. , Low levels of HDL, High Density ... levels of MG being common in the elderly and ... by funding from the British Heart Foundation (BHF) and ...
(Date:8/31/2014)... fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria ... cramps, has been developed by a team at the ... research team has demonstrated that it is possible to ... which would lead to rapid diagnosis of the condition., ... be possible to identify different strains of the disease ...
(Date:8/31/2014)... are not busy attacking us, germs go after each ... spell disaster for the infected microbes: Sometimes viruses actually ... say, expand its diet or better attack its own ... an immune system would robotically destroy anything it recognized ... University have now revealed that one variety of the ...
Breaking Biology News(10 mins):Sugar substance 'kills' good HDL cholesterol, new research finds 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3
... of researchers led by Sharon Herring, MD, MPH, an ... University. She said, "Compared to normal weight women who ... gaining excessively during pregnancy were increased seven-fold among overweight ... they really did. Normal weight women who thought they ...
... Switzerland has shown that carbon nanotubes may be the ... in the advance online edition of the journal ... the search to find ways to "bypass" faulty brain ... like neurons, are highly electrically conductive, form extremely tight ...
... Researchers at the Max Delbrck Center for Molecular Medicine ... (Germany) have identified a gene which enables them to ... colon cancer is going to metastasize. Assistant Professor Dr. ... Birchmeier were able to demonstrate that the gene MACC1 ...
Cached Biology News:Who are you kidding? 2New 'smart' materials for the brain 2Newly identified gene powerful predictor of colon cancer metastasis 2
... Wellpro 384, compatible ... automated liquid handling system ... quickly and accurately prepares ... dilutions. The Wellpro ...
... a new generation bulk reagent dispenser offering ... for pharmaceutical and biotech laboratories. Based on ... Multidrop Combi has been designed for effortless ... l and multiple plate types including 1536. ...
384 well block MBSr. Robot compatible block ejection mechanism. Stackable. (384 well block - holds 384 well plate)...
... 45° Fixed Angle Rotor ... Centra CL2, Centra CL3CL3R, and ... concentration of sputum samples and ... samples. Provides individual aerosol containment. ...
Biology Products: